Viking Therapeutics, Inc.VKTXNASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Under Pressure
Below historical average, modest growth trend.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-39.66%
↓ 764% below average
Average (39q)
-4.59%
Historical baseline
Range
High:45.00%
Low:-63.52%
CAGR
+5.1%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -39.66% |
| Q2 2025 | -41.46% |
| Q1 2025 | -28.12% |
| Q4 2024 | -45.45% |
| Q3 2024 | -10.00% |
| Q2 2024 | 23.08% |
| Q1 2024 | -4.00% |
| Q4 2023 | -8.70% |
| Q3 2023 | -21.05% |
| Q2 2023 | 20.83% |
| Q1 2023 | 4.00% |
| Q4 2022 | -25.00% |
| Q3 2022 | 13.04% |
| Q2 2022 | -9.52% |
| Q1 2022 | -31.25% |
| Q4 2021 | 5.88% |
| Q3 2021 | 15.00% |
| Q2 2021 | -5.26% |
| Q1 2021 | -26.67% |
| Q4 2020 | -15.38% |
| Q3 2020 | 0.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | -30.00% |
| Q4 2019 | -25.63% |
| Q3 2019 | 27.64% |
| Q2 2019 | -60.35% |
| Q1 2019 | 6.67% |
| Q4 2018 | 33.18% |
| Q3 2018 | 15.38% |
| Q2 2018 | -63.52% |
| Q1 2018 | 43.21% |
| Q4 2017 | 36.36% |
| Q3 2017 | -4.76% |
| Q2 2017 | 8.70% |
| Q1 2017 | -27.78% |
| Q4 2016 | 10.00% |
| Q3 2016 | 9.09% |
| Q2 2016 | 45.00% |
| Q1 2016 | 28.57% |
| Q4 2015 | -5.66% |